Streetbeat News

Products Services

ENVB

Enveric Biosciences Canada has been granted U.S. Patent #11858895, which covers aminated psilocybin derivatives and methods of their use. This patent could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the field of psychedelic compounds for therapeutic use.

Portfolio Pulse from Charles Gross

January 02, 2024 | 4:44 pm

HSKA

VNRX

VolitionRx Limited received $13M in milestone payments from Heska Corporation as part of their License and Supply Agreement. The payment was for the successful transfer of the Nu.Q Vet Cancer Test to Heska's Element i+ Immunodiagnostic Analyzer, now called the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor' test.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:43 pm

CDIO

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) stock surged after the company announced that its AI-driven CHD detection test, PrecisionCHD, received a dedicated CPT PLA code from the AMA. This code is crucial for payer billing and is expected to enhance the adoption of the test. The code will become effective on April 1, 2024. The company's CEO emphasized the importance of this milestone in their commercialization strategy and its potential to improve health outcomes and reduce healthcare costs.

Portfolio Pulse from Erica Kollmann

January 02, 2024 | 4:41 pm

SNES

SenesTech, Inc. (NASDAQ:SNES) shares surged after announcing an expanded distribution agreement with Pesterminators Pvt Ltd, which includes the introduction of SenesTech's Evolve and market expansion into the UAE through Pesterminators' subsidiary, TCS Global for General Trading LLC. The expansion is part of SenesTech's regional growth strategy, following the successful integration of their ContraPest products in the Maldives. The agreement includes an initial stocking order for Evolve and an expanded territory that now includes the UAE. SNES shares rose 25.1% to $1.59.

Portfolio Pulse from Akanksha Bakshi

January 02, 2024 | 4:26 pm

MRNA

Oppenheimer analyst Hartaj Singh upgraded Moderna Inc (NASDAQ:MRNA) to Outperform with a price target of $142, citing the company's potential to become a 'five-product commercial company' by 2026. Singh highlighted the expected approvals of Moderna's RSV vaccine (mRNA-1345), influenza vaccine (mRNA-1010), and INT (mRNA-4157), which could utilize the Accelerated Approval pathway. Despite a decline in COVID-19 vaccine sales, there's been an uptick in hospitalizations. Singh anticipates a decrease in OPEX for 2024 and 2025, with sales picking up in 2025. Moderna's shares were up 13.5% to $112.88 following the upgrade.

Portfolio Pulse from Priya Nigam

January 02, 2024 | 4:21 pm

EIS

SPY

USO

Maersk has announced a halt to all shipping transit through the Red Sea and Gulf of Aden after a Maersk vessel, the Maersk Hangzhou, was attacked by Houthi militants. The U.S. Navy intervened, sinking three militant boats. Maersk is rerouting vessels and assessing the situation, with an ongoing investigation into the incident.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:16 pm

CDIO

Cardio Diagnostics' stock is up following the announcement that the American Medical Association has assigned a dedicated CPT PLA code, 0440U, for its PrecisionCHD product.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:03 pm

TGT

Target Corporation (NYSE:TGT) has seen a surge in options activity, with a notable division in sentiment among investors. Benzinga's options scanner detected 17 unusual options activities, with 58% bullish and 41% bearish. The options suggest a targeted price range of $120 to $175 for Target over the last 3 months. The most significant options trades include bearish puts and bullish calls with various expiration dates and strike prices. Target is the sixth-largest retailer in the U.S., with over 1,900 stores and annual sales over $100 billion. The stock price is currently up 0.73% at $143.46, with potential overbought signals from RSI indicators. Target's next earnings report is expected in 56 days.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

HIVE

HUT

Shares of Hut 8 Corp (NASDAQ:HUT) and Hive Digital Technologies Ltd (NASDAQ:HIVE) are rising following Bitcoin's surge above $45,000. Bitcoin's rally, driven by anticipation of a spot Bitcoin ETF approval, is positively impacting these mining companies. Hive Digital recently closed a bought-deal private placement to expand its mining operations and intends to hold its Bitcoin until the next halving. Hut 8 is trending on finance platforms and has seen a significant share price increase over the past month.

Portfolio Pulse from Erica Kollmann

January 02, 2024 | 3:58 pm

TSLA

Tesla Inc (NASDAQ:TSLA) reported increased production and delivery numbers for Q4, surpassing its internal forecast with 1,845,986 vehicles produced and 1,808,581 delivered in full-year 2023. The company is expected to report Q4 earnings on Jan. 24, with an anticipated EPS of 74 cents and revenue of $25.258 billion. Tesla's stock showed volatility, trading slightly down by 0.21% at $248.05 after the update. The EV market is becoming more competitive, especially in China, with BYD surpassing Tesla in Q4 deliveries.

Portfolio Pulse from Adam Eckert

January 02, 2024 | 3:56 pm